Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: A randomized, multicenter study

Hepatology International

Volumn 2, Issue 4, 2008, Pages 486-493

  Yao, Guangbi ^a   Chen, Cheng Wei ^b   Lu, Wei Lun ^c   Ren, Hong ^d   Tan, De Ming ^e   Wang, Yu Ming ^d   Xu, Dao Zheng ^f   Liu, Jessica ^g   Xu, Dong ^g   Llamoso, Cyril ^g  

^a Shanghai Jing An Qu Central Hospital   (China)

^b No 85 Hospital of PLA   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Entecavir; Hepatitis B Virus; Lamivudine

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; VIRUS LOAD;

EID: 57149101516     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9088-8     Document Type: Article

References (24)

1. Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. Lancet 2006;368:896-897
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686
4. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
6. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006;4:936-962
7. Zoulim F. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist? Hepatology 2006;44:1404-1407
8. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696
9. HEPSERA® (adefovir dipivoxil) Package Insert. Gilead Sciences, Inc., 2006
10. Lai CL, Gane E, Hsu CW, Thongsawat S, Wang Y, Chen Y, et al. Global Study Group. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, 2006 Oct 27-31, Boston, MA
11. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Klesczewski K, Tenney D. Assessment at three years shows high barrier to treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006;44(Suppl 1):229A-230A
12. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Eggers B, Xu D, et al. Bristol-Myers Squibb Research and Development. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstract 781]. J Hepatol 2007;46(Suppl 1):S294
13. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the Woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-1245
14. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020
16. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049
17. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444
18. Chang TT, Chao YC, Kaymakoglu S, Cheinquer H, Pessoa M, Gish R, et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral naive HBeAg(+) patients (ETV 022/901) [abstract 109]. Hepatology 2006;44(Suppl 1):229A
19. Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: A randomised double-blind trial in China. Hepatology Int 2007;1:365-372
20. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-1665
21. Shouval D, Akarca US, Hatkjs G, Kitis G, Lai CL, Cheniquer H, et al. Continued virologic and biochemical improvement through 96 week of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027) [abstract 45]. J Hepatol 2006;44(Suppl 2):S21
22. Leung N, Peng C, Sollano J, Lesmana L, Yuen M, Jeffers L, et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (E.A.R.L.Y. study) [abstract 982]. Hepatology 2006;44(Suppl 1):554A
23. Leung N, Peng CY, Sollano J, Lesmana L, Yuen MF, Jeffers L, et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 48 wk results (E.A.R.L.Y. study) [abstract 49]. J Hepatol 2007;46(Suppl 2):S24
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681